Although the compound showed anti-tumor effects in a number of different cancer cell types, MT 63–78 exerted robust growth-inhibitory effects in AR-positive prostate cancer cells that are sensitive to AR-targeted therapeutics, as well as in a number of model systems reflective of castrate-resistant disease. This evidence concerns the gene AR and prostate carcinoma.